- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01558817
Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation
May 9, 2025 updated by: Renee Stapleton, University of Vermont
Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation With Informed Assent: A Pilot Study
Outcomes after in-hospital cardiopulmonary resuscitation (CPR) are very poor, particularly in patients with oxygen dependent chronic obstructive pulmonary disease (COPD) or metastatic cancer.
Recent work found that in-hospital CPR is being performed more often before death with unchanging survival and that fewer CPR survivors are being discharged home, thus suggesting that CPR is increasingly performed without benefit and that the burden of this ineffective treatment is increasing.
Unlike other medical procedures, CPR has become the default provided to all patients even those with tremendously poor outcomes.
It is time to change the paradigm of CPR.
Through comparing an innovative "informed assent" approach toward in-hospital CPR (informing patients that their underlying chronic illness makes outcomes of CPR so poor that CPR is not performed while allowing them to disagree) versus usual care in a group of chronically ill patients with reduced life expectancy, the investigators aspire to demonstrate that CPR delivery can be reduced.
And in addition that DNR status increases, while preserving patient quality of life and decreasing the burden of this ineffective treatment to both patients and families.
If effective, this informed assent intervention has the potential to revolutionize how the investigators discuss CPR with the investigators chronically ill patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- University of Vermont and Fletcher Allen Health Care
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18 years or older
- Oxygen dependent COPD or Advanced Malignancy
- Life expectancy of less than two years
Exclusion Criteria:
- Subjects who have already firmly decided to undergo CPR
- Subjects enrolled in a hospice program
- Subjects unable to speak English
- Subjects incapable of making their own decisions at the time of enrollment
- Subjects cared for by the study investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Informational brochure
Patients receive an informational brochure
|
An informational brochure about CPR will be given without a discussion with a physician.
|
|
Experimental: Intervention
Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
|
Patients receive informed assent approach toward in-hospital CPR outcomes.
Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiopulmonary Resuscitation Preference
Time Frame: Within couple of hours before the intervention and immediately (up to 2 days) after the intervention
|
The primary outcome will be the difference in the proportion of patients in the informed assent intervention and informational brochure groups reporting preferences to be DNR (do not rescusitate).
|
Within couple of hours before the intervention and immediately (up to 2 days) after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression
Time Frame: Baseline (day of intervention) and 2 weeks after intervention
|
Patients' and family members' symptomes of depression will be measured by the PHQ-8 questionnaire.
|
Baseline (day of intervention) and 2 weeks after intervention
|
|
Anxiety
Time Frame: Baseline (day of intervention) and two weeks after intervention
|
Patients and families will complete the GAD-7 questionnaire, a measure of generalized anxiety disorder.
|
Baseline (day of intervention) and two weeks after intervention
|
|
Physician Order for Life Sustaining Treatment (POLST)
Time Frame: Baseline (day of intervention) and 2 weeks after intervention
|
Participants who expressed a preference to be DNR will be asked to complete a POLST form by their physician.
It will also be explained that this can be changed any time the status changes.
|
Baseline (day of intervention) and 2 weeks after intervention
|
|
DNR status preference
Time Frame: Two weeks after the intervention
|
The difference in DNR status preference between patients in the control and invervention group at two weeks after the intervention.
|
Two weeks after the intervention
|
|
Report on acceptability of the informed assent approach
Time Frame: Within couple of hours (up to 2 weeks) after intervention
|
The following questions will be asked:
|
Within couple of hours (up to 2 weeks) after intervention
|
|
Assessment of DNR status change or intervention follow-up from primary physician
Time Frame: Three months after the intervention
|
Contact the physician for each patient at 3 months after the study visit to determine whether there are changes in the DNR status or if the physician has talked with the patients about the status since the study visit.
|
Three months after the intervention
|
|
Resource utilization
Time Frame: Up to 6 months after intervention or until death
|
Record resource utilization for participants that includes hospitalizations, ICU care, use of hospice etc by medical record review.
|
Up to 6 months after intervention or until death
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
February 21, 2012
First Submitted That Met QC Criteria
March 19, 2012
First Posted (Estimated)
March 20, 2012
Study Record Updates
Last Update Posted (Actual)
May 14, 2025
Last Update Submitted That Met QC Criteria
May 9, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PilotCPR001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignancy
-
AstraZenecaCompleted
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
John SarantopoulosNo longer availableAdvanced MalignancyUnited States
-
AstraZenecaCompletedAdvanced Solid Tumor | Advanced Solid MalignancyJapan
-
National University Hospital, SingaporeCompleted
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingAdvanced Gynecological MalignancyChina
-
Kling Biotherapeutics B.V.CompletedAdvanced Solid Tumor MalignancyBelgium, Netherlands
-
NewLink Genetics CorporationTerminatedAdvanced Solid Tumor MalignancyUnited States
Clinical Trials on Informational Brochure
-
Children's Hospital Medical Center, CincinnatiTerminated
-
University of MaineNational Institutes of Health (NIH); National Institute on Aging (NIA); University...CompletedPostural BalanceUnited States
-
University of Illinois at ChicagoNational Cancer Institute (NCI)CompletedHigh Risk for Breast CancerUnited States
-
Betul Esra CevikCompletedAccidental Fall | Fall Prevention | Fall Risk FactorsTurkey (Türkiye)
-
University Paul Sabatier of ToulouseInstitut Claudius Regaud; National Cancer Institute, France; Réseau Onco-Occitanie and other collaboratorsRecruitingBreast CancerFrance
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedDepression | Postpartum DepressionUnited States
-
New York City Department of Health and Mental HygieneActive, not recruitingEmergency PreparednessUnited States
-
Northern Arizona UniversityWithdrawnEarly Childhood CariesUnited States
-
Atlas UniversityCompletedPalliative Patients | Terminal Malignant Tumors | Breathing TechniquesTurkey (Türkiye)
-
University of VirginiaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Exposed PregnancyUnited States